HLB Pharmaceutical Co. Ltd (047920) - Total Liabilities

Latest as of September 2025: ₩46.98 Billion KRW ≈ $31.84 Million USD

Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has total liabilities worth ₩46.98 Billion KRW (≈ $31.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore HLB Pharmaceutical Co. Ltd (047920) long-term investment share to see how much of total assets are deployed in long-term investments.

HLB Pharmaceutical Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how HLB Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HLB Pharmaceutical Co. Ltd asset portfolio.

HLB Pharmaceutical Co. Ltd Competitors by Total Liabilities

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Bhartiya International Limited NSE:BIL	India	Rs8.45 Billion
ReposiTrak NYSE:TRAK	USA	$6.88 Million
Duta Intidaya Tbk PT JK:DAYA	Indonesia	Rp939.10 Billion
Victory Supermarket Chain Ltd TA:VCTR	Israel	ILA1.69 Billion
Korea Information Certificate Authority Inc KQ:053300	Korea	₩170.54 Billion
Alicanto Minerals Ltd AU:AQI	Australia	AU$692.69K
Manulife Holdings Bhd KLSE:1058	Malaysia	RM6.59 Billion
Eugene Corporation KQ:023410	Korea	₩1.32 Trillion

Liability Composition Analysis (2014–2024)

This chart breaks down HLB Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of HLB Pharmaceutical Co. Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HLB Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual total liabilities of HLB Pharmaceutical Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩41.53 Billion ≈ $28.15 Million	-21.93%
2023-12-31	₩53.20 Billion ≈ $36.05 Million	-5.42%
2022-12-31	₩56.25 Billion ≈ $38.12 Million	+14.22%
2021-12-31	₩49.25 Billion ≈ $33.37 Million	-26.27%
2020-12-31	₩66.80 Billion ≈ $45.27 Million	+130.06%
2019-12-31	₩29.04 Billion ≈ $19.68 Million	+49.48%
2018-12-31	₩19.42 Billion ≈ $13.16 Million	-15.71%
2017-12-31	₩23.04 Billion ≈ $15.62 Million	+3.16%
2016-12-31	₩22.34 Billion ≈ $15.14 Million	+76.31%
2015-12-31	₩12.67 Billion ≈ $8.59 Million	-23.77%
2014-12-31	₩16.62 Billion ≈ $11.26 Million	--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$148.92 Million

₩219.75 Billion KRW

Market Cap Rank

#17757 Global

#740 in Korea

Share Price

₩6700.00

Change (1 day)

+3.88%

52-Week Range

₩6170.00 - ₩20900.00

All Time High

₩41100.00